Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies

NCT02441465 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma, Cancer

Interventions

DRUG: Vemurafenib
DRUG: 14C-Labeled Vemurafenib

Sponsor

Hoffmann-La Roche